WP3 has been assigned the task of creating a common data model, to support homogenization of the data creation of relationships among the datasets. This will facilitate comparisons between treatments, patient histories, and clinical and demographic data.
Objectives
- Exploit its ability to combine sets of heterogenic data structures from each source (cooperative groups, hospitals, academic partners, and so on) into such groupings/data types as demographics, clinical information, epidemiology, molecular data, etc.;
- Support future data collection from existing data sources;
- Standardize the format and content of the observational data;
- Create models that will facilitate the establishment of relationships between the data;
- Create a definition for data-use requirements that will be aligned with HARMONY’s needs;
- Harmonize, through the application of algorithms and rule engines, the processing of data to create an organized system for the categorization of findings.
Work Package Partners
Bayer, Celgene, EBMT, ELN, EORTC, GMV, HULAFE, IBSAL, Janssen, LeukaNET, MediUni Wien, Menarini, Novartis, Takeda, Ulm University, UNIBO, University of York.
Work Package Leadership
“Public and private partners are bringing together their best people, data, and knowledge to solve key questions on hematological cancers. These challenges can only be met by applying the most advanced technology.”
Michel van Speybroeck, Director Data Sciences, JPNV-JANSSEN
WP3 Leader
“The Big Data platform, to be developed in WP3, will support data homogenization on a common data model to create relationships and allow advance analysis and studies between treatments, health economics, clinical, molecular, demographic data, etc. The BIG Data infrastructure is developed in such a way that it is capable to incorporate multiple types of heterogeneous data sources in a secured Data Lake infrastructure, normalizing data and incorporating techniques of data quality assessment.”
Rubén Villoria Medina, Project Coordinator, GMV Soluciones Globales Internet (GMV)
WP3 Leader
“”
Lauren Becnel, Vice President Real World Evidence, Pfizer
Co-leader